Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker IRLA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Devesh Gandhi | 880,255 | 7.9% | SCHEDULE 13G ↗ |
| Nov 13, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | SilverArc Capital Management, LLC | 880,255 | 7.9% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Perceptive Life Sciences Master Fund, Ltd. | 912,853 | 8.4% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Joseph Edelman | 912,853 | 8.4% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Perceptive Advisors LLC | 912,853 | 8.4% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | James B. Tananbaum | 652,039 | 6.0% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Foresite Public & Crossover Opportunities Management I, LLC | 163,010 | 1.5% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Foresite Public & Crossover Opportunities Fund I, L.P. | 163,010 | 1.5% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Foresite Capital Management VI, LLC | 489,029 | 4.5% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Foresite Capital Fund VI LP | 489,029 | 4.5% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Neil Shahrestani | 91,789 | 9.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Ikarian Capital, LLC | 91,789 | 9.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Bihua Chen | 108,029 | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Cormorant Asset Management, LP | 108,029 | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Dmitry Balyasny | 97,699 | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Dames GP LLC | 97,699 | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Balyasny Asset Management Holdings LP | 97,699 | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Bam GP LLC | 97,699 | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Balyasny Asset Management L.P. | 97,699 | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Daniel Mack | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Wilmot B. Harkey | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Nantahala Capital Management, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 4, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | William Blank | 55,173 | 5.6% | SCHEDULE 13G ↗ |
| Aug 4, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Matthew Sesterhenn | 55,173 | 5.6% | SCHEDULE 13G ↗ |
| Aug 4, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Squadron Capital Management LLC | 55,173 | 5.6% | SCHEDULE 13G ↗ |
| Aug 4, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Squadron Master Fund LP | 55,173 | 5.6% | SCHEDULE 13G ↗ |
| Jun 10, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Israel A. Englander | 1.40M | 7.2% | SCHEDULE 13G ↗ |
| Jun 10, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Millennium Group Management LLC | 1.40M | 7.2% | SCHEDULE 13G ↗ |
| Jun 10, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Millennium Management LLC | 1.40M | 7.2% | SCHEDULE 13G ↗ |
| Jun 10, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Integrated Core Strategies (US) LLC | 1.40M | 7.2% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Daniel Mack | 4.53M | 7.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Wilmot B. Harkey | 4.53M | 7.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Nantahala Capital Management, LLC | 4.53M | 7.5% | SCHEDULE 13G/A ↗ |
| Mar 5, 2026 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Group One Trading LLC | 5.94M | 10.7% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Daniel Mack | 5.62M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Wilmot B. Harkey | 5.62M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Nantahala Capital Management, LLC | 5.62M | 10.0% | SCHEDULE 13G/A ↗ |
| Oct 30, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Matteo Bruno Renzulli | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Oct 30, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Francesco Micheli | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Oct 30, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Genextra S.p.A. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Daniel Mack | 4.77M | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Wilmot B. Harkey | 4.77M | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G | IRLA IRulya Therapeutics Inc. | Nantahala Capital Management, LLC | 4.77M | 10.0% | SCHEDULE 13G ↗ |
| Apr 30, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Karl Naegler | 1.20M | 2.7% | SCHEDULE 13G/A ↗ |
| Apr 30, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Anta Gkelou | 1.20M | 2.7% | SCHEDULE 13G/A ↗ |
| Apr 30, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Graziano Seghezzi | 1.20M | 2.7% | SCHEDULE 13G/A ↗ |
| Apr 30, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Maina Bhaman | 1.20M | 2.7% | SCHEDULE 13G/A ↗ |
| Apr 30, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Henrijette Richter | 1.20M | 2.7% | SCHEDULE 13G/A ↗ |
| Apr 30, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Antoine Papiernik | 1.20M | 2.7% | SCHEDULE 13G/A ↗ |
| Apr 30, 2025 | SCHEDULE 13G/A (amended) | IRLA IRulya Therapeutics Inc. | Sofinnova Partners SAS, a French Corporation | 1.20M | 2.7% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 10:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances